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Abstract: 
 
Background: Research indicates that diabetes mellitus (DM) may be a risk factor for frailty and 
individuals with DM are more likely to be frail than individuals without DM; however, there is 
limited research in hospitalised older adults. 
 
Objectives: To determine the extent of frailty in hospitalised older adults with and without DM 
using a 16‐item Frailty Risk Score (FRS) and assess the role of frailty in predicting 30‐day 
rehospitalisation, discharge to an institution and in‐hospital mortality. 
 
Methods: The study was a retrospective, cohort, correlational design and secondary analysis of a 
data set consisting of electronic health record data. The sample was older adults hospitalised on 
medicine units. Logistic regression was performed for 30‐day rehospitalisation and discharge 
location. Cox proportional hazards regression was used to analyse time to in‐hospital death and 
weighted using propensity scores. 
 
Results: Of 278 hospitalised older adults, 49% had DM, and the mean FRS was not significantly 
different by DM status (9.6 vs. 9.1, p = 0.07). For 30‐day rehospitalisation, increased FRS was 
associated with significantly increased odds of rehospitalisation (AOR = 1.24, 95% CI [1.01, 
1.51], p = 0.04). Although 81% were admitted from home, 57% were discharged home and 43% 
to an institution. An increased FRS was associated with increased odds of discharge to an 
institution (AOR = 1.48, 95% CI [1.26, 1.74], p < 0.001). The FRS was not significantly 
associated with increased risk of in‐hospital death (p = 0.17), but DM was associated with a 
484% increase in the instantaneous risk of death (AHR = 5.84, 95% CI [1.71, 19.9], p = 0.005). 
 
Conclusion: Diabetes mellitus and frailty were highly prevalent; the mean FRS was not 
significantly different by DM status. Although increased frailty was significantly associated with 
rehospitalisation and discharge to an institution, only DM was significantly associated with in‐
hospital mortality. 
 
Relevance to clinical practice: Frailty assessment may augment clinical assessment and facilitate 
tailoring care and determining optimal outcomes in patients with and without DM. 
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Article: 
 
1 INTRODUCTION 
 
The world population is ageing rapidly, and accelerated growth in older age groups will continue 
to outpace that of younger populations. Currently, older adults over 65 years of age comprise 
14.9% of the USA (He, Goodkind, & Kowal, 2016). Projections indicate that population ageing 
will continue, and there is concern that increasing longevity will be accompanied by the burden 
of morbidity that includes diabetes mellitus (DM) and frailty. Although DM and frailty are 
different syndromes with multifactorial aetiologies and variable clinical manifestations, evidence 
suggests that DM may be a risk factor for frailty and that individuals with DM are more likely to 
be frail than individuals without DM (Chen, Chen, Lin, Peng, & Hwang, 2010). The purpose of 
this study was to: (a) determine the extent of frailty in hospitalised older adults with DM using a 
Frailty Risk Score (FRS) and (b) assess the role of frailty in predicting outcomes including 30‐
day rehospitalisation, discharge to an institution and in‐hospital mortality in older adults with and 
without DM. 
 
2 BACKGROUND 
 
Diabetes mellitus is one of the most common chronic diseases in older adults. In the USA, the 
overall prevalence of DM is estimated at 9.4%; however, among individuals over 65 years of 
age, DM prevalence is 25.2% (Centers for Disease Control and Prevention [CDC], 2017). Of 
those with diagnosed DM, about 5% are diagnosed with type 1 DM (CDC, 2017). The rising 
prevalence of DM is attributed, in part, to population ageing and increasing numbers of 
individuals with type 1 DM living into old age as well as increasing rates of type 2 DM due to 
age‐related pancreatic islet dysfunction and insulin resistance and lifestyle factors such as 
increased sedentary behaviour, unhealthy eating patterns and obesity (American Diabetes 
Association [ADA], 2016). DM is listed as the seventh leading cause of death; individuals with 
DM have a significantly reduced life expectancy and about twice the risk of death compared to 
with people without DM (Centers for Disease Control and Prevention (CDC), 2017). With 
advancing age, individuals with DM experience higher rates of comorbidity and disability 
compared with other age groups (ADA, 2017). The estimated USA total direct and indirect costs 
of DM for 2012 exceeded $245 billion, and average medical expenditures for people with DM 
are 2.3 times higher than expenditures for people without DM (ADA, 2016; Centers for Disease 
Control and Prevention (CDC), 2017). 
 
Frailty is a clinical syndrome of impaired homoeostasis and decreased physiologic capacity 
resulting in diminished ability to resist and recover from physiologic or psychosocial stressors 
(Rodríguez‐Mañas & Sinclair, 2014). Frailty has been operationalised in a variety of ways, but 
two frameworks are applied most often. The frailty phenotype framework developed by Fried 
et al. (2001) identifies five indicators that include weight loss, exhaustion, low physical activity, 
slow walking speed and weakness. Frailty is determined by the presence of at least three of the 
five indicators, and prefrailty, by two of them. The deficit accumulation framework represents 
frailty by the cumulative effects of age‐related deficits that include diseases, signs and 
symptoms, laboratory tests and functional and cognitive impairments that are analysed as an 
index consisting of 30–70 deficits (Mitnitski & Rockwood, 2015). Estimates of the prevalence of 
frailty range from 7.9% to 59.1%, depending on which instruments are applied (Collard, Boter, 
Shoevers, & Oude Voshaar, 2012). In the hospital setting, these frailty prevalence estimates are 
considerably higher and range from 50% to 94% (Basic & Shanley, 2015; Dent, Chapman, 
Howell, Piantadosi, & Visvanathan, 2014; Forti et al., 2014). Frailty is significantly associated 
with numerous adverse outcomes including functional decline, disability, morbidity, 
institutionalisation and early mortality (Collard et al., 2012; Forti et al., 2014). 
 
Research indicates that the prevalence of DM increases in the context of frailty, and frailty 
prevalence is higher in individuals with DM. In one systematic review of community‐living older 
adults, the prevalence of frailty ranged from 5% to 10.7%, whereas in older adults with DM, 
frailty prevalence ranged from 32% to 48% (Cobo, Vázquez, Reviriego, & Rodríguez‐
Mañas, 2016). In other evidence, DM was associated with an increased risk of frailty among 
community‐living adults 60 years and older (N = 1,750) over 3.5 years of follow‐up (OR = 2.18, 
95% CI = [1.42, 3.37]) compared with those without DM (García‐Esquinas et al., 2015). 
Similarly, in a study of 1,754 older adults without DM at baseline, frail individuals (N = 1,754) 
had significantly more DM risk factors (higher haemoglobin A1c and fasting blood glucose, 
lower glomerular filtration rate) than prefrail or nonfrail individuals, and frailty and prefrailty 
were significant independent predictors of DM at 4.4‐year follow‐up (Veronese et al., 2016). 
These findings highlight that frailty and DM often co‐occur, as they are both age‐related 
conditions with multifactorial aetiology (Cobo et al., 2016). Also, underlying pathophysiological 
processes for both DM and frailty involve derangements in neurohormonal, endocrine, 
haematologic, and metabolic function, muscle loss and sarcopenia, and chronic inflammation or 
“inflammaging” (Hunt, Walsh, Voegeli, & Roberts, 2010; Perkisas & Vandewoude, 2016). 
Shared risk factors for frailty and DM include glucose dysregulation, impaired insulin secretion, 
nutrient deficiencies, physical inactivity and obesity (Veronese et al., 2016). Owing to the 
complexity and morbidity associated with DM in older adults, the added vulnerability of frailty 
may identify a higher risk group that requires more intensive evaluation and treatment to prevent 
or mitigate more serious adverse outcomes. While the significance of frailty and DM has been 
established in several community‐living populations, there is only limited research in the acutely 
ill hospitalised older adult. In a study of older hospitalised medical inpatients, Khandelwal et al. 
(2012) found that patients with DM were more not significantly more likely to be frail, but did 
not examine frailty and DM prevalence, associations and outcomes in hospitalised older adults 
with and without DM. Thus, considering the high prevalence and consequences of both DM and 
frailty and the gap in research, there is a need for research to investigate relationships between 
these conditions and outcomes in the acutely ill hospitalised population. 
 
3 METHODS 
 
3.1 Study design and sample 
 
The study was a retrospective, cohort, correlational design and secondary analysis of a data set 
consisting of electronic health record (EHR) clinical data. The sample consisted of 278 adults 
55 years and older who were admitted from 1 June 2010 through 31 August 2011 to medicine 
units at a 938‐bed, not‐for‐profit, academic‐affiliated hospital located in the Southeastern USA. 
The age threshold was determined based on evidence that frailty risk factors and manifestations 
emerge in middle age in some populations (Collard et al., 2012; Morley, Malmstrom, & 
Miller, 2012). The study was originally powered a priori to detect a Cohen's f2 of 0.10 in a 
multiple regression with 20 independent variables with a sample size of 278 patients with 90% 
statistical power, assuming a two‐sided type I error rate of 0.05. Inclusion criteria were an 
overnight stay and laboratory data for four serum biomarkers: albumin, C‐reactive protein 
(CRP), haemoglobin and white blood cell count (WBC). Exclusions were a diagnosis of cancer 
with active treatment. 
 
3.2 Data access 
 
Study data were retrieved from the EHR. The study sample was constructed using a proprietary 
data query tool to access the data storage repository of archived health system clinical data 
(Horvath et al., 2011). The data query tool randomly assigned a unique identifier for construction 
of a deidentified dataset. The data query tool searched the data storage repository with 
delimitations defined by the study inclusion and exclusion criteria. The sampling strategy first 
involved identifying unique hospital admissions of patients 55 years and older during the study 
15‐month time frame. This query yielded 690 total patient hospital admissions. For patients with 
two or more encounters (n = 354; 51%), the first encounter was selected for inclusion in the data 
set. Then, the inclusion criteria of laboratory data for four serum biomarkers (albumin, 
haemoglobin, C‐reactive protein, white blood cell count) were applied, yielding a sample of 281 
unique hospital admissions. These biomarkers are associated systemic inflammation and with 
frailty (Hunt et al., 2010; Soysal et al., 2016). Exclusion criteria were then applied using manual 
search of the record, and three records were excluded. The final sample included 278 hospital 
first encounters. 
 
3.3 Data collection 
 
Data extraction was by manual search of clinical data in the EHR by the first author and two 
registered nurses trained in study procedures. The EHR data sources were electronic PDF files of 
structured information and unstructured narrative physician and nursing notes. Data were 
recorded on a code sheet and then entered into an electronic spreadsheet. Data verification was 
performed by the first author for the entire sample and by a second investigator in 10% of the 
sample. 
 
Table 1. The frailty risk factors and indicators, prevalence on admission in hospitalised older 
adults with and without diabetes mellitus (DM; N = 278)  
Risk factor n(%) Indicator No DM 
(n = 142; 
51%) 
Has DM 
(n = 136; 49%) 
p‐
value 
1. Nutrition issues 222 (80) Weight loss of 15 pounds past 6 months; unplanned 
weight loss; poor appetite; BMI <18.5 or >30 kg/m2 
112 (79) 110 (81) 1.00 
2. Falls 80 (29) Fall admission diagnosis; history of falls 36 (25) 44 (32) 1.00 
 
Risk factor n(%) Indicator No DM 
(n = 142; 
51%) 
Has DM 
(n = 136; 49%) 
p‐
value 
3. Weakness 227 (82) Weakness 118 (83) 109 (80) 1.00 
4. Vision 
impairment 
100 (36) ICD‐9/10 diagnosis (cataracts [corrected, uncorrected], 
glaucoma, macular degeneration, retinopathy, blind) 
38 (27) 62 (46) 0.019 
5. Dyspnoea 104 (37) Dyspnoea or shortness of breath 46 (32) 58 (43) 1.00 
6. Fatigue 249 (90) Fatigue; sleep problems, CPAP at night 125 (88) 124 (91) 1.00 
7. Chronic pain 173 (62) Chronic pain 95 (67) 78 (57) 1.00 
8. Urinary 
incontinence 
66 (24) Urinary incontinence 33 (23) 33 (24) 1.00 
9. Smoking 45 (16) Current smoker 23 (16) 22 (16) 1.00 
10. Depression 97 (35) ICD‐9/10 diagnosis of depression 51 (36) 46 (34) 1.00 
11. Cognition 
problems 
88 (32) ICD‐9/10 diagnosis of dementia, any type, Alzheimer's 
disease, any memory problems; abnormal mental 
status/delirium 
43 (30) 45 (33) 1.00 
12. Social support 
issues 
176 (63) Living alone; single; caregiver concerns; older adult, 
disabled, live alone, & clergy visit 
87 (61) 89 (65) 1.00 
13. CRP or 
hs‐CRP 
246 (89) Abnormal flag, high 127 (89) 119 (88) 1.00 
14. Albumin 258 (93) Abnormal flag, low, <3.6 g/dl 130 (92) 128 (94) 1.00 
15. Haemoglobin 267 (96) Abnormal flag, low. Women, <12.0 g/dl; Men, 13.7 g/dl 134 (94) 133 (98) 1.00 
16. WBC count 206 (74) Abnormal flag, abnormal‐high or low, <3.2 or 
>9.8 × 109/mcL 
98 (69) 108 (79) 0.77 
 
Frailty risk Score 
(0–16) 
9.4 (2.2) Unweighted sum of 16 0/1 indicators for risk factors 
above 
9.1 (2.0) 9.6 (2.3) 0.072 
 
Frailty risk Score 
≥ 9 
189 (68) 
 
89 (63) 100 (74) 0.063 
 
Frailty risk Score 
≥ 10 
135 (49) 
 
65 (46) 70 (51) 0.37 
Nutritional issues = any of BMI ≤18.5 kg/m2, ≥30 kg/m2; unplanned weight loss, or poor appetite. Vision  
problems = any of cataracts, glaucoma, macular degeneration, retinopathy or blind. Cognition problems = any of 
delirium, dementia or impaired memory. Social support issues = any of caregiver concerns, aged/disabled/lives 
alone or clergy visit. Laboratory assay equipment: Albumin (Beckman‐Colter Unicel DXC 600–800, Bromocresol 
Purple [dcp] Timetest Endpoint); CRP and hs‐CRP (Beckman Synchron Systems Neon Infrared Particle 
immunoassay rate methodology); WBC and haemoglobin (Electronic Impedance Differential Lysis Fluorescent 
Flow Cytometry and Colorimetric Measurement). Numbers for Frailty Risk Score are mean (SD). p‐value for 16 
individual Risk Factors given after Bonferroni correction. Chi‐square tests are performed for all analyses except for 
Frailty Risk Score (0–16), where t test results are presented. 
 
A FRS was previously investigated by this author and others (Lekan, Wallace, McCoy, Hu, 
Silva, & Whitson, 2017). The FRS included 16 variables that were identified as frailty risk 
factors based on a conceptual framework derived from theories on biopsychosocial function, 
chronic stress, inflammation, and allostatic load (Beckie, 2012; Cesari, 2011; Hunt et al., 2010; 
Steptoe et al., 2014), the empirical literature on frailty, and variables available in the EHR. The 
biological variables/risk factors included eight symptoms, syndromes and conditions and four 
serum biomarkers. Six of the risk factors were operationally defined by more than one subfactor, 
in which the presence of at least one subfactor resulted in counting the overall risk factor as 
present. The biomarker risk factors were operationalised by the categorical abnormal flag, which 
indicated that the laboratory value fell outside the reference range (see Table 1). The frailty risk 
factors (and subfactors) included fatigue, weakness, dyspnoea, chronic pain, falls (history or 
admission diagnosis), vision impairment (glaucoma, cataracts, macular degeneration, retinopathy 
and blindness), urinary incontinence and nutrition issues (low or high BMI, weight loss and poor 
appetite); the four serum biomarkers that included albumin, C‐reactive protein (CRP), 
haemoglobin and white blood cell count (WBC); three psychological risk factors that included 
cognition problems (delirium, dementia), depression and current smoking; and one social support 
risk factor (single, live alone, and nurse ratings indicating caregiver concerns, and being older, 
disabled, and living alone). 
 
Frailty risk factors were derived from the EHR and counted as “yes = 1” if present and “no = 0” 
if not present. A FRS was created as the unweighted count of the presence of indicators for risk 
factors (theoretical range = 0–16), where higher scores were indicative of increased frailty and 
was calculated for each patient. Based on decision trees from recursive partitioning, a cut‐off 
score of ≥10 was most salient for in‐hospital mortality (area under the ROC curve 
[AUC] = 0.662 (95% CI = [0.568, 0.755], p = 0.003) and a similar cut‐off score of ≥9 was most 
salient for rehospitalisation among those alive at discharge (Lekan et al., 2017). The FRS was 
used to model the outcome variables rehospitalisation within 30 days of discharge, discharge 
location and time to in‐hospital mortality for patients with and without DM. 
 
3.4 Other variables 
 
The diagnosis of DM was determined from the physician admission note listing ICD 9/10 
diagnoses, where DM was identified; determination of type 1 (T1DM) or type 2 (T2DM) 
classification of DM was not available in the EHR. Other variables that were included in 
analyses were age, gender, marital status, race/ethnicity, comorbidity, serum creatinine, impaired 
activities of daily living (ADL), medication count, hyperlipidemia, serum creatinine, unplanned 
surgery, living arrangement, preadmission location and discharge location. Comorbidity was the 
count of ten ICD 9–10 medical diagnoses that were listed on admission. Medication count was 
the number of prescription and nonprescription medications on the admission medication list. All 
data recorded reflected the patient's health status on admission. 
 
3.5 Ethical considerations 
 
Study procedures were approved by the Institutional Review Boards of Duke University Medical 
Center and the University of North Carolina at Greensboro. 
 
3.6 Data analyses 
 
Descriptive statistics using cross‐tabulation tables and chi‐square tests were performed by DM 
groups for individual frailty indicators after Bonferroni multiplicity adjustment. Demographic 
and clinical characteristics were compared by DM groups using similar descriptive statistics or 
within‐group means (M), standard deviations (SD) and ranges for continuous variables. Chi‐
square (if all expected cell counts ≥5) or Fisher's exact tests were performed for categorical 
characteristics and t tests (if normally distributed within group, no extreme outliers and equal 
variances) or Wilcoxon rank‐sum tests for continuous measures. For those still alive at discharge, 
logistic regression was separately performed for 30‐day rehospitalisation and discharge location 
to somewhere other than home. Cox proportional hazards regression was used to analyse time to 
in‐hospital death, which was defined as the length of time between date of admission to 
discharge (considered censored) or death. The proportional hazards assumption was satisfied in 
all Cox regression modelling (p ≥ 0.10). All nonmediation modelling was weighted using inverse 
probability weighting (IPW) based on propensity scores and best practices (Austin & 
Stuart, 2015). The propensity scores were created for DM groups based off of demographic and 
clinical characteristics (except for comorbidity count since presence of individual comorbidities 
was included) to afford better group equivalence, and standardised differences before and after 
weighting were assessed to evaluate whether balance between DM groups had been adequately 
achieved (Austin & Stuart, 2015). For propensity score modelling, race/ethnicity was coded as 
1 = Non‐White and 0 = White, marital status was coded with three indicator variables with 
“married” as the referent group, and all other categorical variables were coded as 1 = present and 
0 = absent. For mediation, the approach and macros by Valeri and VanderWeele (2015) were 
performed. The natural indirect effect was estimated at the median FRS value of 9.0 for patients 
without DM. Here, modelling for these indirect effects of FRS was performed with and without 
covariates in sensitivity analyses and conveyed the same conclusions about mediation. All 
analyses were performed using SAS v9.4 (SAS Institute, Cary, NC). A two‐sided p‐value <0.05 
was considered statistically significant. 
 
4 RESULTS 
 
A total of 278 patients comprised this study. Table 1 describes prevalence of the 16 individual 
FRS indicators by DM status groups, where 49% had DM. The FRS subfactor that had notably 
higher prevalence in the DM group compared with the group without DM was vision impairment 
(46% vs. 27%, Bonferroni p = 0.02). Dyspnoea (43% vs. 32%, Bonferroni p = 1.00), falls (32% 
vs. 25%, Bonferroni p = 1.00) and WBC count abnormally high or low (79% vs. 69%, 
Bonferroni p = 0.77) were greater in prevalence for the DM group versus non‐DM group, but 
were not statistically significant. Mean FRS were close to being significantly different by DM 
groups (DM 9.6 [SD = 2.3] vs. no DM 9.1 [SD = 2.0], p = 0.07). Here, 74% of those with DM 
had FRS ≥9 relative to 63% without DM (p = 0.06). For FRS ≥10, the groups were more evenly 
split (51% for DM vs. 46% for no DM, p = 0.37). 
 
Table 2 provides distributions of demographic and clinical characteristics of the patients with 
and without DM. Here, groups were significantly different on: race/ethnicity (43% Black, 55% 
White for DM vs. 23% Black, 73% White for no DM), BMI (M = 29.7 kg/m2 for DM vs. 
27.5 kg/m2 for no DM on average) and total number of medications (DM M = 13.0 vs. no 
DM M = 10.4). Groups were also significantly different in common cardiovascular morbidity of: 
hypertension (DM 90% vs. no DM 75%), angina (DM 26% vs. no DM 13%), myocardial 
infarction (DM 32% vs. no DM 18%), heart failure (DM 46% vs. no DM 20%), having a 
vascular/pressure ulcer (38% for DM vs. 20% for no DM). Additionally, groups were 
significantly different in other comorbidities including: rheumatoid arthritis (DM 6% vs. no DM 
17%), stroke/transient ischaemic attack (DM 26% vs. no DM 15%), having renal disease (renal 
insufficiency, end‐stage renal disease, dialysis or transplant; DM 64% vs. no DM 42%), 
hyperlipidemia (DM 59% vs. no DM 32%) and typical creatinine levels (DM mean 2.2 mg/dl 
[SD = 2.7] vs. non‐DM 1.8 mg/dl [SD = 1.8]). Propensity score weighting incorporating these 
characteristics were performed when assessing associations of FRS and DM status with 
outcomes besides mediation. Here, 17 of 20 covariates had absolute standardised differences 
(ASDs) below 10% after propensity score weighting (median ASD before weighting = 30%). Of 
those with ASDs 10% or above, COPD had ASD = 14% (before weighting was 1%), CVA/TIA 
had ASD = 12% (before weighting was 29%), and creatinine had ASD = 45% (before weighting 
was 47%). 
 
Table 2. Demographic and clinical characteristics of the hospitalised older adults with and 
without diabetes mellitusa (N = 278) 
Characteristics Overall (N = 278) No DM (n = 142; 
51%) 
Has DM (n = 136; 
49%) 
Test p‐value 
Age (years) 70.1 (10.3)  
[55, 98] 
70.8 (11.0)  
[55, 96] 
69.4 (9.5)  
[55, 98] 
Rank‐sum 0.34 
Gender 
Female 146 (53) 81 (57) 65 (48) Chi‐square 0.12 
Male 132 (47) 61 (43) 71 (52) 
Race/Ethnicity 
Native American 2 (<1) 0 2 (1) Fisher's <0.001 
Asian 2 (<1) 2 (1) 0 
African American 92 (33) 33 (23) 59 (43) 
Other 4 (1) 4 (3) 0 
Caucasian 178 (64) 103 (73) 75 (55) 
Marital status 
Divorced 26 (9) 13 (9) 13 (10) Fisher's 0.99 
Married 142 (51) 72 (51) 70 (51) 
Single/Separated 49 (18) 25 (18) 24 (18) 
Widowed 61 (22) 32 (23) 29 (21) 
BMI (kg/m2) 28.6 (7.6)  
[13.3, 65.4] 
27.5 (7.9)  
[13.3, 61.5] 
29.7 (7.2)  
[14.1, 65.4] 
Rank‐sum 0.002 
≤18.5 kg/m2 16 (6) 12 (8) 4 (3) Chi‐square 0.049 
≥30.0 kg/m2 98 (35) 41 (29) 57 (42) Chi‐square 0.023 
ADL impairment 183 (66) 89 (63) 94 (69) Chi‐square 0.26 
Vascular/pressure 
ulcer 
81 (29) 29 (20) 52 (38) Chi‐square 0.011 
Medication count 11.7 (5.2)  
[0, 31] 
10.4 (5.0)  
[0, 27] 
13.0 (5.1)  
[3, 31] 
Rank‐sum <0.001 
Comorbidity count 3.4 (1.7)  
[0, 7] 
3.1 (1.7)  
[0, 7] 
3.8 (1.7) 
[0, 7] 
t test 0.002 
Unplanned surgery 95 (34) 43 (30) 52 (38) Chi‐square 0.16 
Hypertension 229 (82) 107 (75) 122 (90) Chi‐square 0.002 
Angina 55 (20) 19 (13) 36 (26) Chi‐square 0.006 
Myocardial infarction 69 (25) 26 (18) 43 (32) Chi‐square 0.010 
Heart failure 91 (33) 29 (20) 62 (46) Chi‐square <0.001 
COPD/Asthma 70 (25) 36 (25) 34 (25) Chi‐square 0.95 
Rheumatoid arthritis 32 (12) 24 (17) 8 (6) Chi‐square 0.004 
CVA/TIA 57 (21) 21 (15) 36 (26) Chi‐square 0.016 
Osteoarthritis 137 (49) 78 (55) 59 (43) Chi‐square 0.054 
Renal problem 147 (53) 60 (42) 87 (64) Chi‐square <0.001 
Cancer 63 (23) 37 (26) 26 (19) Chi‐square 0.17 
Characteristics Overall (N = 278) No DM (n = 142; 
51%) 
Has DM (n = 136; 
49%) 
Test p‐value 
Creatinine (mg/dl) 2.2 (2.3)  
[0, 17] 
1.8 (1.8)  
[0, 11] 
2.6 (2.7)  
[0, 17] 
Rank‐sum 0.003 
ADL: activities of daily living; BMI: body mass index; Comorbidity count: the count of ICD  
9/10 medical diagnoses documented on admission; COPD: chronic obstructive pulmonary disease; CVA: 
cerebrovascular accident (stroke); DM: diabetes mellitus; Renal problem: any one of: renal disease, renal 
insufficiency, end‐stage renal disease (ESRD), dialysis or transplant; TIA: transient ischaemic attack. 
a Numbers are n (%) or mean (SD) [Min, Max]. 
 
Table 3. Regression modelling of study outcomesa 
Outcomes FRS interaction FRS mediation FRS independent variable DM vs. no DM 
30‐day rehospitalisation 0.73 
(0.51, 1.05) 
0.09 
1.10 
(0.93, 1.30) 
0.28 
1.24 
(1.01, 1.51) 
0.037 
0.87 
(0.37, 2.04) 
0.75 
Discharge location 0.97 
(0.70, 1.35) 
0.86 
1.05 
(0.95, 1.16) 
0.32 
1.48 
(1.26, 1.74) 
<0.001 
0.85 
(0.44, 1.66) 
0.64 
In‐hospital mortality 0.97 
(0.48, 1.96) 
0.93 
1.00 
(0.93, 1.08) 
0.97 
1.20 
(0.92, 1.56) 
0.17 
5.84 
(1.71, 19.9) 
0.005 
FRS: Frailty Risk Score; DM: diabetes mellitus. 
a Numbers are adjusted odds ratio (AOR), 95% for AOR, p‐value from multivariable logistic  
regression for 30‐day rehospitalisation and discharge location or adjusted hazard ratio (adj. HR), 95% for adj. HR, p‐
value from multivariable Cox proportional hazards regression for in‐hospital mortality, except for FRS mediation 
results are estimated, 95% CI, and p‐value based on results from macros provided from Valeri and VanderWeele 
(2015). Analysis of 30‐day rehospitalisation and discharge location exclude participants who died in‐hospital (n = 13 
excluded). All analyses are adjusted for propensity score weighting based on characteristics in Table 2 except for 
FRS mediation, which included these as covariates. FRS Interaction = moderation analysis where results are 
presented for the pairwise interaction of FRS after centring on mean value of 9.38 and 0/1 indicator variable for 
diabetes (1 = DM). For FRS mediation for in‐hospital mortality, convergence warnings were presented for in‐
hospital mortality and results for the (natural) indirect effect without covariates were as follows: 0.96, (0.88, 
1.06), p = 0.45. DM vs. no DM group are main effects from a model with FRS as an independent variable, as no 
statistically significant interaction or mediation effects were present. 
 
Table 3 presents the results of regression modelling for study outcomes. Among the 265 patients 
alive at discharge, 33 (12.5%) were readmitted within 30 days of discharge. For 30‐day 
rehospitalisation, the effects of the FRS did not depend upon whether the patient had DM 
(interaction p = 0.09). After removing the nonsignificant interaction and as an independent 
variable, increased FRS was associated with significantly increased odds of rehospitalisation 
(AOR = 1.24, 95% CI = [1.01, 1.51], p = 0.04), accounting for propensity score weighting. There 
were no significant differences in odds of rehospitalisation between DM groups in this modelling 
with main effects (p = 0.75). The FRS did not statistically significantly mediate the effect of DM 
status on 30‐day rehospitalisation (p = 0.28). Thus, the FRS only played the role of an 
independent risk factor for 30‐day rehospitalisation and not a mediator of DM effects or a 
moderator. 
 
Regarding discharge disposition, about four‐fifths (81%) of patients were admitted from home 
relative to 19% from another location (e.g. nursing home, another hospital) while among those 
alive at discharge 57% were discharged to home and 43% to another location (e.g. nursing home, 
hospice). For those patients who remained alive at discharge, the effects of the FRS on other 
discharge location did not depend upon whether the patient had DM (interaction p = 0.86). After 
removing the nonsignificant interaction and as an independent variable, increased frailty was 
associated with significantly increased odds of discharge location to an institution (AOR = 1.48, 
95% CI = [1.26, 1.74], p < 0.001), accounting for propensity score weighting and DM status. 
There were no significant differences in odds of other discharge location between DM groups 
(p = 0.64), adjusting for FRS and propensity score weighting. The FRS did not statistically 
significantly mediate the effect of DM status on discharge location (p = 0.32). Again, the FRS 
only played the role of an independent risk factor also for discharge location and not a mediator 
of DM effects or a moderator. 
 
There was a total of 13 in‐hospital deaths. For time to in‐hospital mortality, the effect of the FRS 
did not depend upon whether or not the patient had DM (interaction p = 0.93). After removing 
the nonsignificant interaction and as an independent variable, the FRS was not significantly 
associated with increased risk of death (p = 0.17) after controlling for DM status and propensity 
score weighting. DM was associated with a 484% increase in the instantaneous risk of in‐
hospital death (adjusted HR = 5.84, 95% CI = [1.71, 19.9], p = 0.005), controlling for FRS and 
propensity score weighting. Additionally, the FRS did not statistically significantly mediate the 
effect of DM status on in‐hospital mortality (p = 0.97). Thus, the FRS was not a moderator, 
mediator or independent risk factor for in‐hospital mortality in these analyses. 
 
5 DISCUSSION 
 
There is growing research on frailty in hospitalised populations, and several review articles have 
addressed DM and frailty, but to our knowledge, this is the first study to examine frailty 
prevalence, associations and outcomes in hospitalised medical inpatients with and without DM. 
In the present study, we found that both frailty and DM are highly prevalent in the hospitalised 
older population. 
 
5.1 Frailty prevalence 
 
To assess the extent of frailty in the sample of hospitalised older adults with and without DM, we 
determined that the prevalence of frailty was similarly high and not significantly different in 
patients with and without DM (74% with DM, 63% without DM). This figure falls at the upper 
limit of prevalence rates reported in other studies in medical inpatients, with ranges from 32% to 
94% (Basic & Shanley, 2015; Forti et al., 2014; Joosten, Demuynck, Detroyer, & Milisen, 2014; 
Khandelwal et al., 2012; Wou et al., 2013). Similar findings were noted in a study that 
investigated frailty in older adults admitted to a geriatric medicine unit (N = 427; 30% with DM), 
where thirteen different frailty and functional decline instruments were applied and the 
prevalence of frailty ranged from 24% to 75% (Dent et al., 2014). The variability in frailty 
prevalence is attributed to the use of different frailty assessment methodologies. The lack of 
consensus for frailty assessment is well documented in the literature and is explained by opinions 
that different frailty assessments have different purposes and are applicable in different contexts 
and populations (Cesari, 2011; Rodríguez‐Mañas & Sinclair, 2014). The utilisation of diverse 
frameworks and methodologies in research poses challenges to interpreting and generalising 
research findings. 
 
In the present study, the mean FRS was not significantly different in patients with and without 
DM, a finding that is in concordance with Khandelwal et al. (2012) who found that among 250 
hospitalised older adults, in which 33.2% were classified as frail based on the frailty phenotype 
and about 20% reported DM. The lack of significance between DM groups in the present study 
may be potentially explained by higher comorbidity in the study sample. Higher comorbidity is 
demonstrated in frail hospitalised medical patients (Joosten et al., 2014) and in patients with DM 
(Chen et al., 2010; Khandelwal et al., 2012). In community‐living populations, frail older adults 
with and without DM have greater comorbidity compared with individuals who are not frail 
(Cacciatore et al., 2013; Singh et al., 2012). Findings from a longitudinal cohort study that 
examined DM‐related lifestyle, anthropometric and cardiometabolic risk factors and frailty 
indicate that a one standard deviation in the DM risk score was associated with future frailty 
(Bouillon et al., 2013). Another consideration is the way that DM was measured in the present 
study. We relied on the accuracy of documentation of DM in the medical diagnosis admission 
list in the EHR, but did not have data about DM type, duration or severity. Many reports in the 
literature do not differentiate T1DM from T2DM due to methodological issues and because 
T2DM accounts for 90%–95% of all DM cases (American Diabetes Association, 2016). 
However, T2DM is associated with greater cardiovascular morbidity (stroke, heart attack and 
microvascular complications [retinopathy, nephropathy]), and increased mortality despite a 
shorter duration of disease (American Diabetes Association, 2016). Classifying DM type, 
duration and severity may reveal different frailty levels and risk of outcomes. 
 
Race/ethnicity may have been influential in the higher frailty prevalence in our study and 
insignificant associations in frailty in patients with and without DM. Approximately one‐third of 
the sample was African American, almost twice the number of African Americans had DM 
compared to Caucasians, and there were no significant differences in frailty in African American 
patients with and without DM. Research indicates that the prevalence of both DM and frailty is 
higher in African Americans compared with Caucasians; 13.2% of African Americans over 
20 years of age have DM and are 1.7 times more likely to have DM as non‐Hispanic Caucasians, 
where the proportion with DM is 7.4% (American Diabetes Association, 2017). Few studies have 
examined race/ethnicity in DM and frailty. Data from the Cardiovascular Health Study indicate 
that African American older adults were four times more likely to be frail compared with 
Caucasian older adults (Hirsch et al., 2006). In a study of 998 African Americans enroled in the 
African American Health Study, Chode, Malmstrom, Miller, and Morley (2016) found that 
African Americans with DM were more likely to be frail based on any of four frailty assessment 
tools used compared with those without DM. In contrast to the literature, that there were no 
differences in level of frailty by race in the present study, suggests that other factors were 
potentially influential in the study sample, such as comorbidity, as well as factors associated with 
acute illness and hospitalisation. 
 
5.2 30‐day rehospitalisation 
 
The overall 30‐day rehospitalisation rate in the present study (12.5%) is lower than national US 
estimates which range from 18% to 20% among Medicare recipients (Dungan, 2012; Oates 
et al., 2013). We found that frailty, and not DM, was significantly associated with 30‐day 
rehospitalisation, a finding that has been similarly noted in other research (Forti et al., 2014; 
Wou et al., 2013). Increasing healthcare costs are partly attributable to a small subset of patients, 
particularly those with chronic conditions such as DM, who are prone to disease exacerbation 
and repeated hospitalisations for treatment (Centers for Disease Control and Prevention 
(CDC), 2017); however, our study found that frailty was a better predictor of rehospitalisation 
than DM, and that disease state was not a driver of rehospitalisation. Factors associated with 
rehospitalisation may include unstable health status at discharge, poor understanding of chronic 
disease management, discharge instructions, and medications, and inadequate posthospital care 
or resources (Rubin, Donnell‐Jackson, Jhingan, Golden, & Paranjape, 2014). 
 
5.3 Discharge to institution 
 
In the present study, although the majority of patients were admitted from home, slightly over 
half were discharged home (among those alive at discharge), and frailty (and not DM) was 
significantly associated with increased odds of discharge to an institution. Although discerning 
factors contributing to discharge disposition were outside the scope our study, certain patient 
characteristics may be influential in repeat hospitalisation. For example, in a study of 265 older 
patients on a geriatric ward where 97% were admitted from home, 78% were discharged home 
(Singh et al., 2012). In the study, in which frailty was measured by a 40‐item frailty index, low 
serum albumin, cognitive impairment and functional status were significantly associated with 
discharge status (Singh et al., 2012). In our study, the sample was characterised by higher 
comorbidity, physical impairment and symptom burden (e.g. FRS risk factors: fatigue, weakness, 
dyspnoea, etc.). These factors combined with the stress associated with hospitalisation can 
contribute to prolonged recovery and the need for postdischarge supportive care or rehabilitation 
in an institution (Dent et al., 2014; Rubin et al., 2014). Our findings agree with other research in 
which older medical inpatients were also characterised by poor physical function, high 
comorbidity and high proportion of frailty (Basic & Shanley, 2015; Evans, Sayers, Mitnitski, & 
Rockwood, 2014; Hunt, Walsh, Voegeli, & Roberts, 2013; Wou et al., 2013). We found, as have 
other investigators, that patients with DM had significantly greater comorbidity compared with 
patients without DM (Holman, Hillson, & Young, 2013); however, in our study, propensity score 
weighting was adjusted for the potential impact of confounder imbalances such as comorbidity 
on study outcomes (Schroeder, Jia, & Smaldone, 2016). Moreover, discharge to an institution 
may not always signal a poor outcome since hospitalisation duration has decreased as a cost 
containment strategy, and continuing care in rehabilitation settings may provide more optimal 
transition for the patient and family. The present study was not designed to examine contextual 
factors in discharge disposition. 
 
5.4 In‐hospital mortality 
 
Research indicates that in community‐living older adults, frail patients with DM have a higher 
mortality than nonfrail patients, and the presence of frailty was an independent risk factor for 
mortality even when controlling for comorbidity and disability (Cacciatore et al., 2013; Castro‐
Rodríguez et al., 2016; Jang, 2016; Morley et al., 2012). In the acute care hospital setting, limited 
research indicates that frailty is a significant predictor of mortality; however, in the present 
study, DM, but not frailty, was significantly associated with increased risk of in‐hospital death. 
Using a 55‐item frailty index based on comprehensive geriatric assessment, Evans et al. (2014) 
demonstrated that frailty was independently associated with higher risk of death in 752 medical 
inpatients. Similarly, in a study of 2,125 hospitalised older patients, frailty, as measured by a 
seven‐level frailty scale determined by clinical assessment, predicted in‐hospital mortality (Basic 
& Shanley, 2015). Forti et al. (2014) also found that frailty was significantly associated with in‐
hospital mortality in 685 hospitalised older patients based on the frailty phenotype plus measures 
for cognition and serum albumin. One study of 250 hospitalised medical patients where 20.4% 
had reported DM and 21.7% were frail, frailty was significantly associated with in‐hospital 
mortality but frailty and DM were not examined simultaneously (Khandelwal et al., 2012). 
Limitations of predictive properties of frailty instruments for mortality have been examined. In a 
study that tested five different frailty instruments in older adults admitted to a medical unit 
(N = 677), only four of five instruments significantly but poorly predicted mortality (Wou 
et al., 2013). DM is a recognised independent predictor of in‐hospital mortality (American 
Diabetes Association, 2016; Kirkman et al., 2012). In a study of over 10 million hospital 
admissions, Holman et al. (2013) reported excess mortality among patients with DM; 11.2% of 
admissions had a diagnosis of DM, but 21.5% of in‐hospital mortality occurred in this group. 
Possible explanations for the lack of significance of the FRS for in‐hospital mortality include the 
small number of events, the timing and circumstances of the frailty assessment (on admission), 
and unknown factors associated with cause of death. Frailty is recognised as a dynamic state with 
transitions between levels of frailty (Lee, Auyeung, Leung, Kwok, & Woo, 2014), and frailty 
status in our study sample may have changed with some patients becoming more frail during 
hospitalisation. As the majority of the deaths in our study were in patients with DM, factors 
related to DM may have been influential. For example, life‐threatening alterations in serum 
glucose levels and cardiovascular morbidity are more common in DM (Abdelhafiz, Rodriguez‐
Manas, Morley, & Sinclair, 2015; Chen et al., 2010; Cobo et al., 2016). The context of care may 
also be influential. Clinical and organisational factors such as health professional standards and 
practices, nurse staffing mix and ratios, organisational culture, medical errors and healthcare‐
acquired complications, and other factors may impact quality of care and mortality. Investigation 
of these complex issues was outside the scope of this study. 
 
6 STRENGTHS AND LIMITATIONS 
 
Our study has several strengths. The sample was racially diverse, sample size was sufficient for 
our analysis, and a range of risk factors and confounders were available to inform analyses. The 
retrospective, correlational study design limits generalisability of the findings. Secondary data 
analysis can be problematic as the available data were collected for clinical purposes and not to 
address a particular research question. Clinical data may be subject to provider bias and diligence 
in recording of accurate information. Frailty level may have changed during hospitalisation and 
may be affected by factors other than frailty. Medical acuity could not be determined from the 
available data; illness severity may be a confounding factor in frailty and DM that impact 
outcomes. The study setting was a single institution in the USA, and provider practices may vary 
from those of hospitals without academic affiliations and in other geographic locations. The 
study sample may differ from other populations as biomarkers examined in this study may not be 
routinely ordered. Propensity score weighting was employed to improve balance between DM 
groups on nonfrailty‐related clinical characteristics; however, some slight imbalance remained in 
the proportions of patients with COPD, CVA/TIA, and more than slight imbalance remained in 
creatinine levels. Given the few analyses conducted for outcomes, the false positive rate was left 
at the nominal 0.05 significance level (Westfall, Tobias, & Wolfinger, 2011). 
 
7 CONCLUSION 
 
Both frailty and DM were highly prevalent in a sample of older hospitalised adults, and the mean 
FRS was not significantly different by DM status. Although increased frailty was associated with 
significantly increased odds of rehospitalisation and discharge to an institution, only DM was 
significantly associated with in‐hospital mortality. To our knowledge, this is the first study to 
investigate prevalence, associations and outcomes of DM and frailty in hospitalised medical 
inpatients. These findings contribute to new knowledge about relationships between DM and 
frailty in the acutely ill hospitalised older adult and add to the growing body of evidence that 
supports the clinical relevance of frailty assessment in risk stratification and prediction. Further 
research should explore clinical application of frailty assessment using the FRS and investigate 
the pathophysiological interrelationships between frailty and DM in larger diverse samples and 
settings to help differentiate vulnerable patients and identify primary prevention and intervention 
strategies to reduce risk and mitigate adverse consequences of these often co‐occurring 
conditions. 
 
8 RELEVANCE TO CLINICAL PRACTICE 
 
Adoption of frailty assessment in medical and surgical specialties has increased because of 
research demonstrating its utility in risk stratification and clinical decision‐making to prevent 
rehospitalisation and discharge planning to prevent discharge planning to prevent worsening 
morbidity and functional decline requiring long term institutionalisation. Our study findings 
suggest that frailty assessment may be a useful adjunct to clinical judgement to identify more 
vulnerable patients that may require more nurse‐intensive interventions and interdisciplinary care 
coordination. Indeed, frailty assessment has been advocated for all patients with DM and all 
older people should be screened for DM (Cobo et al., 2016). Frailty assessment can not only 
distinguish patients who are at higher risk and more likely to deteriorate and allow clinicians to 
focus on the highest risk of early intensive interventions, but also identify patients who are at a 
lower risk and more likely to benefit from more invasive or hazardous treatments or 
interventions (Singh et al., 2012). Recent reviews indicate a plethora of frailty assessment tools; 
however, many involve extra data collection and complex analyses that are burdensome to the 
patient and clinician, and lack clinical utility (Rodríguez‐Mañas & Sinclair, 2014). The FRS 
aggregates empirically based biopsychosocial risk factors for a clinically relevant approach that 
may facilitate care planning and be easy for nurses to understand and use. Using readily available 
data from the EHR as demonstrated here for the FRS may expedite adoption of frailty 
assessment into nursing practice through efficiencies gained from using existing data sources. 
 
Recommended approaches to frailty assessment advocate a two‐part strategy with a frailty 
screening measure (such as the FRS used in the present study) followed by comprehensive 
geriatric assessment (Evans et al., 2014). In clinical practice, it may also be important to consider 
frailty as a biometric like blood pressure and pulse that changes based on a constellation of other 
dynamic factors. Thus, frailty assessment during hospitalisation may provide an early alert to 
providers of significant changes in condition that require immediate attention. Information 
technology can be applied to calculate and track a patient's frailty score throughout 
hospitalisation and could aid in evaluating patient response to interventions. Further research can 
investigate feasibility and implementation in nursing practice. 
 
One of the greatest hazards of hospitalisation that increases risk of both frailty and DM and 
contribute to numerous poor outcomes is preventable functional decline. The risk of progressive 
muscle atrophy, weakness and sarcopenia leading to irreversible functional decline and disability 
is magnified in DM and frailty (Cobo et al., 2016; Dent, Visvanathan, Piantadosi, & 
Chapman, 2012). Thus, the FRS on admission can target the higher risk frail patients for 
interventions to promote mobility and function (e.g. graduated muscle strengthening 
programmes, range of motion, early mobilisation and prehabilitation) in order to mitigate the 
muscle atrophy and sarcopenia that is central to both frailty and DM (Chen et al., 2010; Cobo 
et al., 2016). 
 
The FRS used in the present study included several nutritional indicators that were present on 
admission (BMI, weight loss and poor appetite). However, nutritional inadequacy is a significant 
problem during hospitalisation. In a study of 100 hospitalised older adults, where 40% were 
malnourished and 44% were at risk of malnutrition, poor nutritional status significantly predicted 
frailty (Dent et al., 2012). Weight loss that occurs in both frailty and DM is associated with loss 
of muscle and bone resulting in a decrease in muscle strength and function. In DM, weight loss 
may due to poorly controlled hyperglycaemia or to antidiabetic medications, whereas in frailty, 
loss of appetite is an underlying aetiology (Chen et al., 2010; Jang, 2016). Thus, carefully 
assessing nutritional indicators on admission and ongoing would be central to person‐centred 
care and coordinated interdisciplinary efforts for optimal nutritional outcomes. 
 
The use of biomarkers in frailty assessment provides physiologic data that can further 
characterise frailty risk. The biomarkers used in our study can be further investigated to 
determine the optimal timing, cut‐point and the panel of biomarkers for risk stratification 
(Beckie, 2012; Perkisas & Vandewoude, 2016). Additional biomarkers may also be considered, 
for example, haemoglobin A1c and fasting serum glucose levels (which were not available in our 
study) may help differentiate risk in both DM and frailty (Bouillon et al., 2013; Castro‐
Rodríguez et al., 2016). The availability of biomarkers in the EHR and inclusion of biomarkers 
as part of the frailty assessment is an important consideration as there may be additional costs 
and burdens to patients and clinicians that would impact feasibility. 
 
Diabetes mellitus management guidelines have undergone revision in recent years to address the 
older adult with DM and frailty. Healthcare providers should understand that management of 
DM must take into account the heterogeneity of older adults and the influence of frailty. The 
principles of DM management in healthy older adults are similar to those in younger persons, but 
special considerations address comorbidity, cognitive disorders, and disability in older adults, 
and frailty (American Diabetes Association, 2016; Jang, 2016; Veronese et al., 2016). Stricter 
glycemic control is associated with increased risk of hypoglycaemia, falls, cognitive decline and 
mortality in frail older persons with DM (Abdelhafiz et al.,2015; Chen et al., 2010); thus, recent 
recommendations liberalise the metabolic target range of haemoglobin A1c to <8.5% in the 
context of multimorbidity, poor health and frailty (American Diabetes Association, 2016; Chen 
et al., 2010; Cobo et al., 2016; Kirkman et al., 2012). The American Diabetic Association (2016) 
recommends a standardised hospital‐wide, surveillance programme hypoglycaemia prevention 
bundle to prevent iatrogenic hypoglycaemia and nurse‐initiated hypoglycaemia treatment 
protocol to immediately address hypoglycaemia. 
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